CD274 and renal cell adenocarcinoma: In addition, sarcomatoid tumors demonstrated lower incidence of PBRM1 mutations, angiogenesis markers, CDKN2A/B alterations, and PD-L1 expression, which helps to develop possible molecular subtypes for further RCC tumor characterization [41].